US · Healthcare · Biotechnology
EPS came in at 0.18 against a street estimate of 0.06 — a beat of 200.0%.
Analysts rate ACADIA Pharmaceuticals Inc a buy (15 buy, 4 hold, 1 sell out of 20) with an average price target of $30.58.
CONFIDENT ACADIA beat Q2 expectations with 17% revenue growth, raised DAYBUE guidance to $480–510M (from $460–490M), and expects remlifanserin Phase II ADP data Sept–Oct. Both commercial franchises performing strongly; pipeline catalyst approaching. Q2 2026 U.S. driving both brands. Europe DAYBUE launch (Germany Q4 2026) expected to contribute <15% of 2028 $700M guidance. Named patient supply programs active globally. Analysts pressed remlifanserin effect size, STIX patient composition, and European DAYBUE pricing. Management noted 0.4 powering defensible vs. pimavanserin data; STIX mix diverse (new + conversion); EU pricing deferred pending AMNOG negotiations post-6-month free period. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 24.91% |
| BlackRock Inc | 13.07% |
| State Street Corp | 5.27% |
| Vanguard Portfolio Management, LLC | 5.13% |
| RTW INVESTMENTS, LLC | 4.15% |
| Vanguard Capital Management, LLC | 3.35% |
| Dimensional Fund Advisors, Inc. | 2.14% |
| Geode Capital Management, LLC | 1.95% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 ACADIA PHARMACEUTICALS INC. - 8-K SUMMARY HEADLINE NUMBERS • Primary endpoint (SAPS-H+D at week 6): Remlifanserin 60 mg showed -12.6 change versus p | 2026-09-24 |
| Company announcement · Q3 2026 ACADIA PHARMACEUTICALS INC. - 8-K SUMMARY HEADLINE NUMBERS • Filing date: September 11, 2026 • Company: Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) • | 2026-09-11 |
| Quarterly report · Q2 2026 ACADIA PHARMACEUTICALS INC. – 10-Q SUMMARY Q2 2026 (Period Ended June 30, 2026) --- HEADLINE NUMBERS • Cash and equivalents: $384.985 million (up f | 2026-08-05 |
| Results announced · Q3 2026 ACADIA PHARMACEUTICALS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 total revenues: $308 million, up 16% year-over-year (GAAP) and u | 2026-08-04 |
| Board / officer change · Q2 2026 ACADIA PHARMACEUTICALS INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 29, 2026 • 5,209,670 additional shares authorized under equity | 2026-05-29 |
| Quarterly report · Q1 2026 ACADIA PHARMACEUTICALS INC. — 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Product Sales (Q1 2026): $268.1 million — up 9.7% fr | 2026-05-07 |
| Results announced · Q2 2026 ACADIA PHARMACEUTICALS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total Q1 2026 revenues: $268 million (up 10% vs. Q1 2025's $244 million) | 2026-05-06 |
| Board / officer change · Q2 2026 ACADIA PHARMACEUTICALS INC. - 8-K SUMMARY HEADLINE NUMBERS • Report Date: April 27, 2026 (filed April 30, 2026) • Company: Acadia Pharmaceuticals Inc | 2026-05-01 |
Readable in the app.
| Announcement | Date |
|---|---|
| Full year 2026 total revenue guidance increased to $1.24-$1.30 billion Acadia Pharmaceuticals reported strong Q2 2026 results with total revenue of $308 million, up 16% year-over-year. Key drug DAYBUE achieved $125 million in sales (up 30%), driven by strong ad | 2026-08-04 |
| Full year 2026 revenue guidance of $1.22-$1.28 billion provided Acadia Pharmaceuticals reported strong 2025 results, achieving over $1 billion in annual revenue for the first time. Full-year GAAP revenues reached $1.07 billion (12% growth), with non-GAAP | 2026-02-25 |
| Narrowing and raising NUPLAZID guidance; updating DAYBUE guidance Acadia Pharmaceuticals reported strong third-quarter 2025 results with total revenues of $278.6 million, up 11% year-over-year. The company's two main drugs performed well: NUPLAZID (pimavan | 2025-11-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ACADIA Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.